ArticleJournal of clinical medicine research2025
Plasma Level of Stromal Cell-Derived Factor-1 Provides Insight Into Statin Response, But Not Into Left Ventricular Dysfunction in New Unstable Angina.
Article in Journal of clinical medicine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stromal cell-derived factor-1 (SDF-1) is a chemokine that regulates atherogenesis, angiogenesis, and multiple physiological processes. Dyslipidemia can contribute to low plasma SDF-1 disturbing its vascular repair functions and elevating cardiovascular risk. Statin therapy is recommended for patients with acute coronary syndrome irrespective of low-density lipoprotein-cholesterol (LDL-C) levels. This study aimed to evaluate the potential associations of plasma SDF-1 levels with LDL-C levels, coronary occlusion-based disease severity, low left ventricular ejection fraction (LVEF) values, and statin therapy in patients with unstable angina (UA). Methods: Patients with new UA (n = 108) were selected from Coronary Care Unit, King Abdulaziz University Hospital. The exclusion criteria included previous history of myocardial infarction, cardiac valvular problems, myocarditis, liver dysfunction, and recent acute infection. The demographic and clinical features were collected. Disease severity and LVEF values were determined. Plasma SDF-1, LDL-C, and troponin levels were measured. Results: There were poor correlations between plasma SDF-1 level, and sociodemographic features and risk factors except with LDL-C, where it showed a significant correlation. Furthermore, plasma SDF-1 showed non-significant variations with LVEF values and troponin peak levels. In contrast, plasma SDF-1 declined significantly in statin-treated patients, regardless of LDL-C level, compared with those untreated. The receiver operating characteristic (ROC) curve for SDF-1 test showed good accuracy. Conclusion: In patients with severe UA, plasma SDF-1 level showed significant variations with LDL-C levels and statin therapy suggesting that it can give insight into response to statin therapy regardless of LDL-C level. The ROC analysis showed favorable characteristics suggesting a potential usefulness of plasma SDF-1 assay to discriminate the statin-treated patients from those untreated. This novel approach highlights SDF-1 potential as a biomarker for monitoring statin therapy and predicting risks for adverse events in UA. Furthermore, it could pave the way for longitudinal studies with repeated measurements of plasma SDF-1 to evaluate its role as a prognostic indicator for major adverse cardiovascular events besides the other cardiovascular disease risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.